Rare Disease Day Update: FRAXA Features GEXVal’s FRAXA-DVI Completion and FDA Orphan Drug Designation

株式會社GEXVal
February 28, 2026

FRAXA Research Foundation Features GEXVal's Completion of FRAXA-DVI Program and FDA Orphan Drug Designation

On Rare Disease Day （February 28, 2026）, we are delighted to announce that FRAXA Research Foundation¹⁾ has featured GEXVal Inc.'s (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan; hereinafter "GEXVal") development program on their website.

The original article can be viewed here:
[GEXVal Completes FRAXA-DVI, Receives FDA Orphan Drug Designation, and Prepares for Phase 2a Trial]
(URL: https://www.fraxa.org/gexval-completes-fraxa-dvi-receives-fda-orphan-drug-designation-and-prepares-for-phase-2a-trial/)

Through our innovative pharmacoinformatics technology, GEXVal is dedicated to addressing unmet medical needs and engaging in clinical development, with a focus on rare diseases, ensuring that no patient is left behind. We are committed to delivering novel and life changing therapeutic options to patients and their families as quickly as possible.

1) About FRAXA Research Foundation (FRAXA): FRAXA is a nonprofit organization headquartered in Massachusetts, USA, dedicated to supporting research and raising awareness for the development of treatments for Fragile X Syndrome.
For more information, visit https://www.fraxa.org

2) About Fragile X syndrome (FXS): Fragile X syndrome is a rare genetic condition associated with features of autism spectrum disorder. According to FRAXA Research Foundation, it is considered the most common genetic cause of autism and intellectual disabilities.
For more information:
- National Organization for Rare Disorders (NORD): https://rarediseases.org/rare-diseases/fragile-x-syndrome/
- Orphanet: https://www.orpha.net/en/disease/detail/908?name=fxs&mode=name
- FRAXA Research Foundation: https://www.fraxa.org

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com